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.2013.10Abstract Background: It has been suggested that overtreatment of infants with congenital adrenal
hyperplasia (CAH) due to 21-hydroxylase deﬁciency might affect their growth and ﬁnal height.
Objective: To assess the axiological parameters of infants with CAH due to 21-hydroxylase deﬁ-
ciency from their ﬁrst presentation in neonatal period and during infancy, in an attempt to decide
the optimum doses of glucocorticoid, mineralocorticoid and salt therapy that can achieve androgen
suppression, prevent life-threatening salt-wasting crises, and allow normal growth velocity for age.
Materials and methods: Retrospective study conducted in the Diabetes Endocrine and Metabolism
Pediatric Unit at Children’s Hospital, Cairo University included baseline and follow-up data of 28
infants with 21-hydroxylase deﬁciency.
Results: Median age at presentation was 34 days. Lower doses of hydrocortisone (<20 mg/m2/
day) were associated with better growth, not reaching a statistical signiﬁcance. Delta change in
length standard deviation score (SDS) was signiﬁcantly higher in males (p= 0.01). Delta change
in length and weight SDS of cases with mean basal length SDS below 2 were signiﬁcantly higher
than those with mean basal length SDS above 2 (p= 0.02 and 0.04 respectively). No correlationsw Children Hospital (Abu El
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58 M.M. Hassan et al.were found between delta height-SDS and age at diagnosis, duration of follow-up, glucocrticoid or
mineralocorticoid dosing.
Conclusion: Poor growth in infants with salt wasting CAH was not related to age at diagnosis and
start of therapy, doses of glucocorticoid, ﬂudrocortisones, or saline therapy. Male sex and mean
basal length SDS below 2 were associated with a more favorable growth catch up. Further
prospective studies with inclusion of intercurrent illnesses and nutritional status are needed.
ª 2013 Production and hosting by Elsevier B.V. on behalf of The Egyptian Pediatric Association.Introduction
Congenital adrenal hyperplasia (CAH) is an autosomal reces-
sive disorder due most commonly, to deﬁciency of 21-hydroxylase
(21-OH) enzyme action that typically reduces cortisol and
aldosterone secretion while simultaneously increasing andro-
gen production.1 Growth is considered a key concern in the
management of congenital adrenal hyperplasia (CAH), as in-
fants often fail to reach their target height. Treatment of
CAH is based on the administration of glucocorticoid and
mineralocorticoid, which decrease ACTH-stimulated excess
of adrenal androgen. Higher doses of hydrocortisone may be
needed to achieve satisfactory androgen suppression, with sub-
sequent hypercortisolism.2,3 The combination of hyperandrog-
enism and hypercortisolism most likely explains the short adult
stature frequently observed in treated children with CAH.4
Whether this decreased height potential is caused by inade-
quate suppression of adrenal androgens, excess steroid treat-
ment or the salt wasting state itself is a matter of debate.5
Current evidence suggests that infancy and peripubertal
periods are the time periods when height outcome is most sen-
sitive to glucocorticoid dose.6,7 Individualized treatment ap-
proaches have been suggested to prevent growth failure.8
Monitoring of treatment during these critical periods is largely
based on the assessment of a certain biochemical investigation
with growth velocity and skeletal maturation. The growth
velocity and skeletal maturation are the most accurate predic-
tors of long-term outcome of somatic growth.9
In this study we aimed to assess the axiological parameters
of infants with congenital adrenal hyperplasia from their ﬁrst
presentation in the neonatal period and during infancy, in an
attempt to decide the optimum doses of glucocorticoid, miner-
alocorticoid and salt therapy that can achieve androgen sup-
pression, prevent life-threatening salt-wasting crises, and
allow normal growth velocity for age.
Subjects and methods
This was a retrospective study that included 28 infants {21
females (46, xx), and 7 males (46, xy)}. The infants were diag-
nosed as congenital adrenal hyperplasia and were followed-up
regularly at The Diabetes Endocrine and Metabolism Pediatric
Unit (DEMPU), Children’s Hospital of the Cairo University.
The study protocol was approved by the University’s Research
Ethics Committee and was conducted in accordance with the
University’s bylaws for human research.
The records of all infants and the baseline and data of fol-
low-up visits were reviewed with emphasis on the age at pre-
sentation, sex of rearing, presenting complaint, salt wasting
symptoms and signs, parental consanguinity, family history
of CAH or any abortion or prenatal death. The number of saltwasting crises and number of admissions since start of therapy
for each patient were also recorded.
All anthropometric data including length, weight at base-
line and at follow-up visits were reviewed. The supine length
was measured by using a Harpenden infanotometer and the
weight was measured by using an electronic digital scale. Mea-
surements were taken and recorded every 3 months and the
Growth vision computer software provided by Novo Nordisk
was employed to assess length standard deviation score (SDS)
and weight SDS to assess linear growth and weight gain for
adjustment of the daily hydrocortisone dose.
According to the protocol adopted at our unit (DEMPU),
all infants were treated with daily SC/IM hydrocortisone ther-
apy calculated in mg/m2/day and given in two equally divided
doses till the age of 9 months, then on oral hydrocortisone (lo-
cally manufactured Micort tablets, 10 mg/tab) with the total
daily dose divided three times daily. They were also given daily
oral ﬂudrocortisone at a dose of 0.05–0.15 mg and advised dai-
ly salt therapy. Hydrocortisone doses were adjusted so that
17OH progesterone done every 3 months reaches target level
of biochemical control (5–10 ng/ml, 15.2–30.3 nmol/L), and
salt wasting crises are prevented. Hydrocortisone doses were
doubled with intercurrent illnesses or surgery to be returned
to original dose after recovery after recovery.
Statistical analysis
For statistical analysis the mean values of the daily hydrocorti-
sone and ﬂudrocortisone doses were calculated for the whole
period of the follow up included in the study. Datamanagement
and analysis were performed using SPSS for windows, version
11.0.0. The numerical data were statistically presented in terms
of range, mean, standard deviation, median and interquartile
range (IQR). Categorical data were summarized as percentages.
Comparisons between numerical variables within groups
at two different time points were done by Student’s paired
t-test for parametric data or Wilcoxon Signed Rank test for
non-parametric data. Comparisons between numerical vari-
ables of two groups were done by Student’s unpaired t-test
for parametric data or Mann–Whitney Rank Sum test for
non-parametric data. Correlations were tested by Pearson
co-efﬁciency for parametric variables and Spearman’s rank corre-
lation test for non-parametric variables.10 All p-values are two
sidedand considered signiﬁcantwhen p-values were less than 0.05.
Results
Table 1 illustrates the general characteristics and growth
parameters during the studied period. The mean dose of
hydrocortisone therapy was 20.2 ± 6.1 mg/m2/day (range:
8.6–36 mg/m2/day), and for ﬂudrocortisone therapy the mean
Table 1 General characteristics, basal and ﬁnal anthropometric data of the studied cases (n= 28).
General characteristics of the studied cases (n= 28)
Genetic sex:
Males (n;%) 7 (25%)
Females (n;%) 21 (75%)
Initial sex of rearing:
Males (n;%) 17 (60.7%)
Females (n;%) 11 (39.3%)
Age at presentation (days):
Median (range & IQRa) 34 (range: 7–180, IQRa: 14.25–80)
Presenting complaint:
Salt-wasting (n;%) 17 (60.7%)
Ambiguous genitalia (n;%) 11 (39.3%)
Duration of follow-up (mos):
Median (range) 13.14 (range: 10–23, IQR*: 1.05–1.37)
Parental consanguinity (n;%) 17 (60.7%)
+ve FHb of CAHc (n;%) 11 (39.3%)
Basal Final Delta change p-Value
Length SDSd: Mean ± SD 2.3 ± 1.7 2.0 ± 1.5 0.3 ± 1.5 0.100
Weight SDSd:
Mean ± SD 1.7 ± 1.5 1.6 ± 1.1 0.1 ± 1.1 0.442
Growth velocity cm/year:
Mean ± SD 13.6 ± 4.7
Growth velocity SDSd:
Mean ± SD 0.2 ± 1.6
a IQR: interquartile range.
b FH: family history.
c CAH: congenital adrenal hyperplasia.
d SDS: standard deviation score.
Growth in infants with congenital adrenal hyperplasia due to 21-hydroxylase deﬁciency 59dose was 24.6 ± 8.8 lg/m2/day (range: from 11.5 to 41.0 lg/
m2/day). Mean length SDS at the end point was higher, with
a delta change 0.3 ± 1.5 (mean ± SD), but not reaching a sta-
tistical signiﬁcance (p= 0.1). The mean weight SDS showed
an insigniﬁcant improvement from 1.7 ± 1.5 SDS at the
start to 1.6 ± 1.1 SDS by the end of the studied period
(p= 0.4) with no detectable increase in weight in 7 infants
(25%) during the studied period.
Salt losing symptoms and signs were the most common pre-
sentation followed by ambiguous genitalia. The median age at
presentation was 34 days (range 7–180 days). Genital ambigu-
ity was overlooked in 10/21 (47.6%) females with incorrect
male gender assignment and delay in diagnosis. Delay in diag-
nosis was also found in 5/7 (71.4%) males who were misdiag-
nosed as sepsis, gastroenteritis and other conditions, with a
delay in diagnosis to up to 180 days (6 months). Parental con-
sanguinity was found in 60.7%, and positive family history of
similar condition was found in 39.3% of subjects.
Fourteen infants (50%) were controlled on a mean hydro-
cortisone dose <20 mg/m2/day, while the other 14 infants
(50%) needed a mean dose P20 mg/m2/day. The length and
weight SDS of both groups showed statistically insigniﬁcant
changes from baseline to the end of the follow up period. How-
ever, those on low dose showed improvement in both linear
and ponderal growths although not reaching a statistical sig-
niﬁcance. Salt-receiving (n= 18) and non salt-receiving infants
(n= 10) showed insigniﬁcant changes in their length SDS
(p= 0.6, 0.08 respectively), but non salt-receiving infants
(n= 10) showed a signiﬁcant increase in their weight SDS
(p= 0.048), (Table 2).
Males had a signiﬁcant increase in their length and weight
SDS on steroid therapy (p= 0.001, 0.04, respectively) while fe-males showed insigniﬁcant changes. The length and weight
SDS of infants with a basal mean Ht SDSP 2 (n= 11)
showed insigniﬁcant changes from baseline measurements to
the end of the follow up period (p= 0.4 and 0.2 respectively).
While, the length SDS of cases with basal mean Ht SDS below
2 (n= 17) showed a signiﬁcant increase at the end of the fol-
low up period (p= 0.03), but the weight SDS showed an insig-
niﬁcant decrease (p= 0.1), (Table 2).
The delta length SDS and delta weight SDS, growth veloc-
ity and growth velocity SDS showed insigniﬁcant differences in
relation to hydrocortisone dosing or salt supplementation (Ta-
ble 3). While the delta change in length SDS was signiﬁcantly
higher in males when compared to females (p= 0.01). The del-
ta change in weight SDS, growth velocity and growth velocity
SDS were comparable between both sexes (p= 0.2, 0.1, and
0.09 respectively). The delta change in length and weight
SDS were signiﬁcantly higher in infants with basal mean Ht
SDS below 2 compared to those with basal mean Ht SDS
above 2 (p= 0.02 and 0.04 respectively) (Table 3).
A signiﬁcant proportionate correlation was found between D
length-SDS and D weight-SDS (r= 0.5, p= 0.006), as well as
growth velocity (r= 0.7, p less than 0.001).A signiﬁcant propor-
tionate correlation was also found between D weight-SDS and
duration of follow-up (r= 0.5, p= 0.04). No signiﬁcant corre-
lation was found between either D length-SDS or D weight-SDS
and hydrocortisone or ﬂuodrocortisone doses. Other tested cor-
relations were not statistically signiﬁcant (Table 4).
Discussion
To our knowledge, there are few previous reports of growth
parameters in infants with 21-OHD 11–13. It is not clear which
Table 2 Comparison of length SDS & weight SDS before the start of treatment and at the end of the study period among subgroups
(n= 28).
Before the start of steroids At the study period p-Value
Mean ± SD Mean ± SD
Groups Length SDSa
Low HCb dose (<20 mg/m2/day) (n= 14) 2.6 ± 1.7 2.0 ± 1.7 0.077
High HCb dose(P20 mg/m2/day) (n= 14) 2.1 ± 1.6 2.0 ± 1.3 0.821
Salt-receiving (n= 18) 2.3 ± 1.8 2.1 ± 1.6 0.560
Non-salt-receiving (n= 10) 2.5 ± 1.5 1.8 ± 1.3 0.084
Males (n= 7) 3.4 ± 1.7 2.0 ± 1.8 0.001 c
Females (n= 21) 2.0 ± 1.5 2.0 ± 1.4 0.622
Basal height SDSa P2 (n= 11) 0.66 ± 0.89 1.04 ± 1.39 0.460
Basal height SDSa <2 (n= 17) 3.44 ± 0.96 2.58 ± 1.25 0.033 c
Weight SDSa
Low HCb dose (<20 mg/m2/day) (n= 14) 1.7 ± 1.7 1.4 ± 1.2 0.420
High HCb dose (<20 mg/m2/day) (n= 14) 1.7 ± 1.2 1.8 ± 1.0 0.868
Salt-receiving (n= 18) 1.5 ± 1.4 1.7 ± 1.1 0.644
Non-salt-receiving (n= 10) 2.0 ± 1.7 1.4 ± 1.1 0.048 c
Males (n= 7) 2.0 ± 1.8 1.5 ± 1.4 0.039 c
Females (n= 21) 1.6 ± 1.4 1.6 ± 1.0 0.897
Basal height SDSa P2 (n= 11) 0.400 ± 1.339 0.773 ± 1.184 0.233
Basal height SDSa <2 (n= 17) 2.512 ± 0.863 2.088 ± 0.625 0.111
a SDS: standard deviation score.
b HC=Hydrocortisone.
c p-Value is signiﬁcant if <0.05.
Table 3 Comparison of anthropometric parameters of subgroups (n= 28).
Mean ± SD
D Length- SDSb D Weight-SDSb Growth velocity Growth velocity-SDSb
Low HCa dose (n= 14) 0.6 ± 1.2 0.3 ± 1.2 13.9 ± 5.0 0.3 ± 1.1
High HCa dose (n= 14) 0.03 ± 1.8 0.04 ± 1.0 13.4 ± 4.5 0.6 ± 1.9
p-Value 0.260 0.344 0.772 0.188
Salt-receiving (n= 18) 0.2 ± 1.4 0.2 ± 1.0 13.1 ± 4.3 0.03 ± 1.5
Non-salt receiving (n= 10) 0.6 ± 1.9 0.7 ± 0.9 14.6 ± 5.4 0.07 ± 1.91
p-Value 0.179 0.092 0.422 0.592
Males (n= 7) 1.4 ± 0.7 0.5 ± 0.5 16.1 ± 3.3 0.7 ± 1.0
Females (n= 21) 0.02 ± 1.60 0.03 ± 1.2 12.8 ± 4.9 0.5 ± 1.7
p-Value 0.012* 0.221 0.111 0.088
Basal Ht SDSb P2 (n= 11) 0.47 ± 1.85 0.37 ± 0.97 13.34 ± 5.39 0.81 ± 1.82
Basal Ht SDSb <2 (n= 17) 0.85 ± 1.08 0.42 ± 1.03 13.84 ± 4.35 0.27 ± 1.34
p-Value 0.023 c 0.038 c 0.787 0.082
a HC= hydrocortisone.
b SDS: standard deviation score.
c p-Value is signiﬁcant if <0.05.
60 M.M. Hassan et al.factors contribute to growth impairment in CAH. Previous
studies investigated associations with clinical phenotype, age
at start of treatment, hormonal control, and glucocorticoids
dosage.14–18 It was suggested that the high hydrocortisone
doses used during infancy and early childhood, critical periods
of rapid growth, lead to growth suppression and may lead to
an irreversible loss of adult length.19,20
In this retrospective study we have carried out a cross sec-
tional periodic evaluation of a longitudinal follow up, focusing
on the effect of the dose of hydrocortisone on the growth rate of
28 childrenwith the salt losing formof congenital adrenal hyper-
plasia due to 21 hydroxylase deﬁciency. We analyzed these
parameters in relation to the dose of hydrocortisone, ﬂudrocor-tisone, salt supplementation, age at presentation and gender. To
normalize data, length, weight, delta change and growth veloc-
ity were analyzed in terms of standard deviation scores (SDSs).
Regarding sex preponderance, this study revealed a female
to male ratio of 3:1. This is similar to previous reports in which
the majority of cases were females.21,22 However, because the
gene for this disorder is autosomally recessive, it occurs equally
in males and females. This female preponderance can be
explained by the fact that males are signiﬁcantly under-
diagnosed and that some of the affected males die without a
correct diagnosis as they present only with salt losing crisis
and with no genital ambiguity that arouses suspicion of par-
ents or physicians.23
Table 4 Correlations of D Length-SDS and D Weight-SDS
and other clinical variables.
D Length- SDS a D Weight-SDS a
r-Coeﬀ. p-Value r-Coeﬀ. p-Value
D Weight-SDSa 0.510 0.006b – –
Age at presentation 0.144 0.511 0.297 0.168
Duration of follow-up 0.272 0.275 0.485 0.041b
Hydrocortisone dose 0.146 0.459 0.051 0.808
Fludrocortisone dose 0.064 0.765 0.310 0.141
Growth-velocity 0.286 0.140 0.054 0.784
Growth-velocity SDS a 0.655 0.0002b 0.314 0.103
a SDS: standard deviation score.
b p-Value is signiﬁcant if <0.05.
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180 days). Genital ambiguity was overlooked in 10/21
(47.6%) females with incorrect male gender assignment and
delay in diagnosis. Delay in diagnosis was also found in 5/7
(71.4%) males who were misdiagnosed as sepsis, gastroenteri-
tis and other conditions, with a delay in diagnosis to up to
180 days (6 months). Survival of those infants to that age in-
spite of the missed diagnosis can be explained by their receiv-
ing repeated ﬂuid therapy and steroids empirically for other
illnesses. Parental consanguinity was found in 60.7%. Analo-
gous data have been reported by Bhanji and colleagues who
found parental consanguinity in 52% of cases,24 while this per-
cent decreased to 33% in the study of Al-Maghribi.25 The high
rate of consanguinity in the Egyptian population might be
responsible for the high incidence of CAH and necessitates ge-
netic counseling for affected families. Positive family history of
similar condition was found in 39.3% of subjects. This almost
agreed with Bhanji and collegues who reported siblings with a
similar condition in 30% of their cases.24 However, we noted
that the presence of a similar condition did not help in early
diagnosis, as 6 out of 11 (54.5%) with a positive family history
remained unrecognized within the 1st month of life.
Salt losing symptoms and signs were the most common pre-
sentation followed by ambiguous genitalia, with unrecognized
ambiguity and incorrect gender assignment in 10/21 (47.6%)
females. This is different from the observations of Torok
et al.22 and Al-Maghribi,25 who reported genital ambiguity
as the most common presentation followed by salt losing
manifestations.
All of the infants received hydrocortisone therapy in a
mean dose of 20.2 ± 6.1 mg/m2/day (range: 8.6–36.0 mg/m2/
day), with ﬂudrocortisone therapy in a mean dose of
24.6 ± 8.8 lg/m2/day (range: 11.5–41.0 lg/m2/day), and in
18 infants (64.3%) parents supplied regular supplemental salt
therapy.
On revising the growth parameters among our case series,
we found that the mean length and weight–SDS were negative
before and remained so after therapy with an insigniﬁcant in-
crease. A catch up effect was observed during the studied per-
iod as the delta length SDS and delta weight SDS reached
positive values. The mean growth velocity of infants under
treatment was 13.643 ± 4.696 but growth velocity-SDS was
still negative (0.154 ± 1.605). Six infants (21.4%) length
did not increase during the studied period, all of them were
girls with 5 on salt supplementation and 4 on hydrocortisone
more than 20 mg/m2/24 h.The mean length SDS in our study was much lower than
that reported by de Almeida and associates;26 and Volkl
et al.27 but slightly lower than that reported by Aycan and col-
leagues.28 This lower length SDS of our study population
may be related to bad compliance and poor control with
consequent increased steroid dosage. Other factors such as
nutritional status, inter-current illnesses, and the different
genetic growth potentials could contribute.
No correlations were found between D Ht-SDS, DWt-SDS
or growth velocity and glucocrticoid dosing. This was in line
with Manoli et al.21 who found no correlation between hydro-
cortisone dosage and weight SDS. But contradicts Jaaskelai-
nen & Voutilainen,29 who reported a signiﬁcant negative
correlation between the mean daily glucocorticoid dose and
height velocity in the ﬁrst year of life. However, our cases with
hydrocortisone dose less than20 mg/m2/24 h showed some
improvement in their length SDS and weight SDS over the
studied period although not reaching a statistical signiﬁcance;
which means that this group of infants showed an improve-
ment in their length SDS on treatment.
On the other hand, caseswith hydrocortisone dosemore than
20 mg/m2/24 h showed minimal changes in length and weight
SDS at the end of the follow up period. In addition, the delta
change in weight, length SDS, growth velocity, and growth
velocity SDS of cases with low dose were higher when compared
to cases with higher doses but not reaching a statistical signiﬁ-
cance. Two out of 14 (14.3%) cases on low cortisone dose had
poor growth rate versus 4/14 (28.6%) of the high cortisone dose
group (p= 0.6). These ﬁndings agree with Stikkelbroeck et al.
who reported that glucocorticoid dose has growth-suppressing
effects during the age interval of 6 months to 1 year.30
Speiser & White31 stated that salt intake may add some
adrenal suppression but our results did not conﬁrm this ﬁnd-
ing. We found that the Ht-SDS showed statistically insigniﬁ-
cant changes from baseline to the end of the follow up
period in cases with or without salt supplementation. How-
ever, cases without salt supplementation showed a signiﬁcant
increase in their weight SDS over time. The delta length SDS
and delta weight SDS, growth velocity and growth velocity
SDS showed insigniﬁcant differences in relation to salt
supplementation.
Males had a signiﬁcant increase in their length and weight-
SDS after therapy and the delta change in length-SDS was sig-
niﬁcantly higher in males when compared to females. Our re-
sults revealed that those who were initially shorter acquired
signiﬁcantly more length by the end of the period of follow
up compared to infants who were not pathologically short.
Also, the D length-SDS and D weight-SDS were signiﬁcantly
higher in the initially shorter group. We suggest that regardless
of the glucocorticoid dose, those who were initially pathologi-
cally shorter gained a signiﬁcantly higher (better) length SDS
compared to those who were not pathologically short. Growth
velocity and growth velocity SDS were comparable between
both groups although GV and GVSDS were higher in the ﬁrst
group but the difference did not reach a statistical signiﬁcance.
The present study had some limitations being an observa-
tional retrospective study. Also, it is to be mentioned that glu-
cocorticoid and ﬂudrocortisone doses were collected in detail,
based on patient records (prescribed doses), but no systematic
information was available about compliance or about the
frequency of temporary overdosing with intercurrent illnesses,
and assessment of nutritional status was not available.
62 M.M. Hassan et al.Conclusions
In conclusion, infants with salt wasting CAH had poor lin-
ear growth and gain of weight during infancy, which was
related neither to the age at diagnosis and start of therapy,
nor to the doses of glucocorticoids, ﬂudrocortisones, or sal-
ine replacement therapy. More favorable growth catch up
was found in male infants, and in those pathologically
short at presentation and start of therapy. Lower doses
of hydrocortisone (<20 mg/m2/day), compared to higher
doses, were also associated with better growth, but not
reaching a statistical signiﬁcance. Further prospective stud-
ies with a larger number of cases and with inclusion of
intercurrent illnesses and nutritional status in infants with
CAH are warranted.
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